INTERNATIONAL MEETING ON INFLUENZA VACCINE EFFECTIVENESS (VE)
Centre International de Conférences Genève (CICG), Geneva, Switzerland
3 to 4 December 2012
FINAL LIST OF PARTICIPANTS

PARTICIPANTS

Dr Melissa Andrew, Assistant Professor of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Dr Nicholas Andrews, Statistics Modelling and Economics Department, Health Protection Agency, London, United Kingdom

Dr Eduardo Azziz-Baumgartner, Epidemiology and Prevention Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States of America

Dr Novilia Sjafri Bachtiar, Senior Manager of Surveillance & Clinical Trial Division, PT Bio Farma, Bandung, Indonesia

Dr Edward A. Belongia, Epidemiologist, Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, WI, United States of America

Dr Cornelia Betsch, Psychologist, Scientific Manager of the, Center for Empirical Research in Economics and Behavioral Science (CEREB), University of Erfurt, Erfurt, Germany

Dr Walter E. Beyer, Virologist, Department of Viroscience, Erasmus Medical Center (MC), Rotterdam, CA Netherlands

Dr Rick Bright, Deputy Director - Influenza Division, Office of Biomedical Advanced Research & Development Authority (BARDA), US Department of Health and Human Services (HHS), Washington, DC, United States of America

Dr Abdullah Brooks, Head of Infectious Diseases Unit, Health Systems Infectious Diseases Division, Dhaka, Bangladesh

Dr Shobha Broor, Microbiology, All India Institute of Medical Sciences, New Delhi, India

Dr Jesus Castilla, Seccion de Vigilancia de Enfermedades Transmisibles, Public Health Institute, Pamplona, Navarra, Spain

Dr Meral Akcay Ciblak, Virology and Fundamental Immunology Unit, National Influenza Reference Lab. Capa-Istanbul, Istanbul University, Fatih/Istanbul, Turkey

Dr Wil Clara, Acting Director of the Influenza Program & Country Representative - El Salvador, Embassy of the United States in San Salvador, El Salvador, San Salvador, El Salvador

Dr Jean-Marie Cohen, Gérant, Epidémiologie et Santé publique, Open Rome, Réseau d'Observation des maladies et des épidémies, Paris, France

Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (SAR), China
Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, University of Bergen, Bergen, Norway

Dr Aldiouma Diallo, Responsable Pole Sante, UMR URMITE / SDEE Niakhar, Institut de Recherche pour le Developpement, Dakar, Senegal

Dr Masafumi Endo, Applied Research Department, The Chemo-Sero-Therapeutic Research Institute, (KAKETSUKEN), Kumamoto, Japan

Professor Janet Englund, Professor at University of Washington, Infectious Disease Program, University of Washington, Seattle, WA, United States of America

Dr Jill Mary Ferdinand, Epidemiology and Prevention Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States of America

Dr Douglas Fleming, Director, Birmingham Research Unit, Royal College of General Practitioners, Birmingham, United Kingdom

Dr Alicia Fry, Epidemiology and Prevention Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States of America

Dr Bruce Gellin, Director, National Vaccine Programme, Department of Health and Human Services, Washington DC, United States of America

Dr Ed Geuns, Abbott B.V., Hoofddorp, VB, Netherlands

Dr Nina Grundmann, Research Associate, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland

Dr Guillermo Herrera-Taracena, GMA Leader for Infectious Diseases and Vaccines, Johnson & Johnson, United States of America

Dr Le Kim Hoa, Vice Director, QC & QA, R&D/Head of QA, Institute of Vaccine and Medical Biologicals, Nha Trang, Khanh Hoa Province, Viet Nam

Professor Li-Min Huang, Chief, Division of Infectious Diseases, Department of Pediatrics, Taiwan University Hospital, Taipei, Taiwan, China

Dr Michael Jackson, Group Health Cooperative, Seattle WA, United States of America

Dr Mark Jit, Mathematical Modeller, Modelling and Economics Unit, Health Protection Agency, London, United Kingdom

Dr Ruth Karron, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

Dr Heath Kelly, Head, Epidemiology and Public Health, VIDRL, Victoria, Australia

Dr Yoichiro Kino, General Manager, Second Research Department, The Chemo-Sero-Therapeutic Research Institute, (KAKETSUKEN), Kumamoto, Japan

Dr Esther Kissling, EpiConcept, London, United Kingdom

Ms Janna Klein Breteler, Preparedness and Response Unit, Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, Netherlands

Dr Prasad S. Kulkarni, Medical Director, Serum Institute of India Ltd., Pune, Maharashtra, India

Dr Kathryn Lafond, Epidemiologist, Influenza Division, Centers for Disease Control and Prevention, Atlanta, United States of America

Dr Amparo Larrauri, Area de Vigilancia de la Salud Publica, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
Dr Stefan Ma, Deputy Director in the Epidemiology and Disease Control Division, Ministry of Health, Singapore, Singapore

Dr Anna Macura-Biegun, Senior Director, Head of Medical Affairs and Clinical Development Department, Crucell, Berne, Switzerland

Dr Shabir Madhi, Department of Pediatrics, Chris Hani-Baragwanath Hospital, Bertiham, South Africa

Dr Cedric Mahe, Sanofi Pasteur MSD, Lyon, France

Dr Jim McMenamin, Health Protection Scotland, National Services Scotland, Glasgow, United Kingdom

Professor Elizabeth Miller, Head., Immunisation Department, Health Protection Agency, Centre for Infections, London, United Kingdom

Dr Ali A. Mohammadi, President, Global Health and Security Consultants, Grand-Saconnex, Switzerland

Professor Arnold Monto, The Thomas Francis Jr. Professor, Epidemiology, The University of Michigan School of Public Health, Ann Arbor, MI, United States of America

Dr Alain Moren, Director, Epidemiology Department, EpiConcept, Paris, France

Dr Joshua Mott, KEMRI/CDC Research and Public Health collaboration, Nairobi, Kenya

Ms Tamara Music, Manager, Influenza Vaccines & Code Compliance, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland

Dr Takeshi Naruse, Chemo Sero Therapeutic Research Institute, The (Kaketsuken), Kumamoto, Japan

Professor Thu Van Nguyen, General Director, The Company for Vaccine and Biologicals Production No.1, National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam

Professor Angus Nicoll, Senior Expert, Influenza Coordination, European Centre for Disease Prevention and Control, Stockholm, Sweden

Dr Baltazar Nunez, Instituto Nacional de Saude, Lisbon, Portugal

Dr Sonja Olsen, Acting Director, Department of Disease Control, Centers for Disease Control and Prevention, Nonthaburi, Thailand

Dr Justin Ortiz, Assistant Professor of Medicine, Associate Director, International Respiratory and Severe Illness Center (INTERSECT), University of Washington Medical Center, Seattle, WA, United States of America

Dr Joerdis J. Ott, Consultant, Vevey, Switzerland

Dr Bram Palache, Global Scientific and Public Affairs Director, Influenza Vaccines, Abbott Biologics B.V., Weesp, Netherlands

Dr Richard Pebody, Communicable Disease Surveillance Centre, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom

Dr Stéphanie Pépin, Clinical R&D, Sanofi Pasteur, Marcy l'Etoile, France
Dr Yuri Pervikov, Consultant, Geneva, Switzerland
Professor Punnee Pitisuttithum, Clinical Infectious Disease Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Dr Douglas R. Pratt, DVRPA/OVRR/CBER, Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, Maryland, United States of America

Dr Alexander R Precioso, Medical Director, Clinical Trials, Clinical Trials Division, Instituto Butantan, São Paulo, Brazil

Dr Joan Puig-Barbera, Centro Superior de Investigacion en Salud Publica, Valencia, Spain

Professor Isaias Raw, Investigator and President of the Technical Scientific Council, Instituto Butantan, São Paulo, Brazil

Dr Annicka Reuss, Department for Infectious Disease Epidemiology, Division 36 Respiratory Diseases, Robert Koch Institute, Berlin, Germany

Dr Marc Rondy, EpiConcept, Paris, France

Professor Larisa Rudenko, Head, Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russian Federation

Ms Kim Sampson, Executive Director, Asia-Pacific Alliance for the Control of Influenza Ltd, Melbourne, Victoria, Australia

Dr Daphne Schmid, Crucell, Berne, Switzerland

Dr Jo Ellen Schweinle, Biomedical Advanced Research and Development Authority, Washington DC, United States of America

Dr Vivek Shinde, GlaxoSmithKline Biologicals SA, Rixensart, Belgium

Dr Georgi Shukarev, Crucell, Berne, Switzerland

Dr Francois Simondon, Executive Director, Epidemiology, Sanofi Pasteur MSD, Vaccines for life, Lyon, France

Professor Lone Simonsen, Research Professor, Department of Global Health, George Washington University, Washington DC, United States of America

Dr Danuta Skowronski, Physician Epidemiologist, BC Centre for Disease Control Society, Vancouver BC, Canada

Dr Wayne Sullender, University of Alabama Birmingham, Birmingham, Alabama, United States of America

Dr Sheena Sullivan, Scientist, Epidemiology, WHO Influenza Centre, Victoria, North Melbourne, Australia

Dr Masato Tashiro, Director, Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan
Dr Beverly Taylor, IFPMA - IVS SPR Coordinator, Head of Technology and Scientific Affairs, Novartis Vaccines & Diagnostics Ltd, Liverpool, United Kingdom

Dr Mark Thompson, Epidemiology and Prevention Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States of America

Dr Theodore F. Tsai, Sr. VP, Scientific Affairs, Novartis Vaccines, Cambridge, MA, United States of America

Dr Vadim Tsvetnitsky, Influenza Project Leader, Vaccine Development Global Program, PATH, Washington DC, United States of America

Dr Marta Valenciano, Senior Epidemiologist, Epidemiology Department, EpiConcept, Madrid, Spain

Dr Maria van Kerkhove, Imperial College London, London, United Kingdom

Dr Serge Vandewitte, Abbott B.V., Hoofddorp, VB, Netherlands

Dr Lodewijk Venhuizen, Senior Regulatory Affairs Manager, Crucell, Berne, Switzerland

Dr Guy Vernet, Fondation Merieux, France

Professor Timo Vesikari, Vaccine Research Center, University of Tampere School of Medicine, Tampere, Finland

Dr Niteen Wairagkar, Senior Program Officer, Infectious Diseases, Global Health Program, The Bill and Melinda Gates Foundation, Seattle, WA, United States of America

Dr Leonoor Wijnans, Clinical Assessor, Pharmacotherapeutic group IV (anti-infectives), Medicines Evaluation Board (MEB), Utrecht, Netherlands

Dr Ponthip Wirachwong, Director of Biological Research Group, Research and Development Institute, The Government Pharmaceutical Organization, Bangkok, Thailand

Dr K. Zaman, Scientist and Epidemiologist and Co-reviewer of CRS, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh

Dr Suizan Zhou, Surveillance Coordinator, China-U.S. Cooperative Program on Emerging and Re-emerging Infectious Diseases, U.S. Centers for Disease Control and Prevention, Beijing, China

CDC SECRETARIAT

Dr Joseph S. Bresee, Chief, Epidemiology and Prevention Branch, Influenza Division, Center for Disease Control and Prevention, Atlanta, GA, United States of America

Dr Marc-Alain Widdowson, Senior Service Fellow, Respiratory and Enteric Virus Branch, Center for Disease Control and Prevention, Atlanta, GA, United States of America
WHO REGIONAL OFFICES

Ms Pernille Jorgensen, Influenza & other Respiratory Pathogens, WHO Regional Office for Europe, Copenhagen, Denmark

Ms Alba Maria Ropero Alvarez, Advisor on Immunization, Comprehensive Family Immunization, Area of Family and Community Health, Pan American Health Organization, Washington DC, United States of America

WHO/HQ SECRETARIAT

Dr Sylvie Briand, Director, PED, Pandemic and Epidemic Diseases, WHO HQ/HSE, Geneva

Dr Martin Friede, IEA, ADGO office of the Assistant DG, WHO HQ/HIS, Geneva

Dr Keiji Fukuda, Assistant Director-General HSE, WHO HQ, Geneva

Dr Joachim Hombach, Senior Adviser, IVR Initiative for Vaccine Research, WHO HQ/FWC, Geneva

Dr Raymond Hutubessy, IMR, Implementation Research, WHO HQ/FWC, Geneva

Dr Marie-Paule Kieny, Assistant Director-General HIS, Health Systems and Innovation, WHO HQ, Geneva

Dr Anthony Mounts, HIP, Influenza, Hepatitis and PIP Framework, WHO HQ/HES, Geneva

Dr Laszlo Palkonyay, QSS, Quality, Safety and Standards, WHO HQ/HIS, Geneva

Dr Cathy Ellen Roth, Adviser, HEA, ADGO office of the Assistant DG, WHO HQ/HSE, Geneva

Dr Nahoko Shindo, HIP, Influenza, Hepatitis and PIP Framework, WHO HQ/HES, Geneva

Ms Erin Sparrow, Project Officer, IEA, ADGO office of the Assistant DG, WHO HQ/HIS, Geneva

Dr John S. Tam, IVR Initiative for Vaccine Research, WHO HQ/FWC, Geneva

Dr Wenqing Zhang, HIP, Influenza, Hepatitis and PIP Framework, WHO HQ/HES, Geneva